AstraZeneca's Imfinzi Plus Chemo Approved by FDA for Endometrial Cancer

AstraZeneca's cancer drug Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The approval follows the results of the DUO-E Phase III trial, which demonstrated that Imfinzi, in combination with chemotherapy drugs carboplatin and paclitaxel, reduced the risk of disease progression or death by 58% compared to chemotherapy alone.

Endometrial cancer is the fourth most common cancer among women in the United States, with over 66,000 diagnoses and nearly 12,000 deaths reported in 2022. While the five-year survival rate for early-stage diagnosis is approximately 80-90%, there remains a significant need for effective treatments for advanced cases. The approval of Imfinzi provides a new treatment option for patients with dMMR endometrial cancer, addressing an important medical need in this patient population.